C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on June 18, 2025, regarding events occurring at the Company's Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "CCCC".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure amendments rather than financial performance.
Material Changes and Voting Results
Stockholders approved several key proposals at the Annual Meeting:
- Capital Structure Amendment: Stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The Certificate of Amendment was filed with the Delaware Secretary of State and became effective immediately.
- Director Elections: Ronald Harold Wilfred Cooper, Donna Grogan, M.D., and Steven Hoerter were elected as Class II directors to serve until the 2028 annual meeting.
- Executive Compensation: Stockholders cast a non-binding advisory vote to approve the compensation of named executive officers.
- Auditor Ratification: Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future operations, or new risk factors. The primary focus is the successful execution of the shareholder vote and the legal amendment to the corporate charter.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment with the Delaware Secretary of State.
- Review the definitive proxy statement on Schedule 14A (filed April 29, 2025) for detailed rationale behind the share authorization increase.
- Monitor the Company's capital allocation strategy given the doubling of authorized shares from 150 million to 300 million.
- Confirm the tenure of the newly elected Class II directors through the 2028 annual meeting.